Rapamycin encapsulated in dual-responsive micelles for cancer therapy

Biomaterials

Volumn 34, Issue 4, 2013, Pages 1115-1127

  Chen, Yi Chun ^a   Lo, Chun Liang ^b   Lin, Yu Fen ^c   Hsiue, Ging Ho ^a,c  

^a NATIONAL TSING HUA UNIVERSITY   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c CHUNG YUAN CHRISTIAN UNIVERSITY   (Taiwan)

Author keywords

Autophagy; Intracellular drug delivery; PH responsive; Polymeric micelles; Rapamycin

Indexed keywords

AUTOPHAGY; INTRACELLULAR DRUG DELIVERY; PH-RESPONSIVE; POLYMERIC MICELLE; RAPAMYCIN;

CELL DEATH; DRUG DELIVERY; ONCOLOGY; SOLUBILITY;

MICELLES;

COPOLYMER; POLY(ETHYLENE GLYCOL) B POLY(LACTIDE); POLY(ETHYLENE GLYCOL) B POLY[N (2 HYDROXYPROPYL)METHACRYLAMIDE DILACTATE] CO [N (2 HYDROXYPROPYL)METHACRYLAMIDE CO HISTIDINE]; RAPAMYCIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOLYSOSOME; CANCER INHIBITION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG STABILITY; ENCAPSULATION; ENDOCYTOSIS; HEAT SHOCK; HUMAN; HUMAN CELL; MICELLE; MOUSE; NEOPLASM; NONHUMAN; PARTICLE SIZE; PH; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; HCT116 CELLS; HELA CELLS; HUMANS; MICE; MICELLES; NANOCAPSULES; NEOPLASMS, EXPERIMENTAL; SIROLIMUS; TREATMENT OUTCOME;

BOVINAE;

EID: 84870337265     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.10.034     Document Type: Article

References (56)

1. Vezina C., Kudelski A., Sehgal S.N. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot (Tokyo) 1975, 28:721-726.
2. Abraham R.T., Wiederrecht G.J. Immunopharmacology of rapamycin 1. Annu Rev Immunol 1996, 14:483-510.
3. Sabatini D.M. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 2006, 6:729-734.
4. Marinov M., Fischer B., Arcaro A. Targeting mTOR signaling in lung cancer. Crit Rev Oncol Hematol 2007, 63:172-182.
5. Ji J., Zheng P.-S. Activation of mTOR signaling pathway contributes to survival of cervical cancer cells. Gynecol Oncol 2010, 117:103-108.
6. Gulhati P., Cai Q., Li J., Liu J., Rychahou P.G., Qiu S., et al. Targeted inhibition of mammalian target of rapamycin signaling inhibits tumorigenesis of colorectal cancer. Clin Cancer Res 2009, 15:7207-7216.
7. Noh W.-C., Mondesire W.H., Peng J., Jian W., Zhang H., Dong J., et al. Determinants of rapamycin sensitivity in breast cancer cells. Clin Cancer Res 2004, 10:1013-1023.
8. Kroemer G., Jaattela M. Lysosomes and autophagy in cell death control. Nat Rev Cancer 2005, 5:886-897.
9. Mizushima N., Levine B., Cuervo A.M., Klionsky D.J. Autophagy fights disease through cellular self-digestion. Nature 2008, 451:1069-1075.
10. Faivre S., Kroemer G., Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 2006, 5:671-688.
11. Wanner K., Hipp S., Oelsner M., Ringshausen I., Bogner C., Peschel C., et al. Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab. Br J Haematol 2006, 134:475-484.
12. Raught B., Gingras A.-C., Sonenberg N. The target of rapamycin (TOR) proteins. Proc Natl Acad Sci U S A 2001, 98:7037-7044.
13. Buck E., Eyzaguirre A., Brown E., Petti F., McCormack S., Haley J.D., et al. Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors. Mol Cancer Ther 2006, 5:2676-2684.
14. Guba M., Koehl G.E., Neppl E., Doenecke A., Steinbauer M., Schlitt H.J., et al. Dosing of rapamycin is critical to achieve an optimal antiangiogenic effect against cancer. Transpl Int 2005, 18:89-94.
15. Seeliger H., Guba M., Kleespies A., Jauch K.-W., Bruns C. Role of mTOR in solid tumor systems: a therapeutical target against primary tumor growth, metastases, and angiogenesis. Cancer Metastasis Rev 2007, 26:611-621.
16. Simamora P., Alvarez J.M., Yalkowsky S.H. Solubilization of rapamycin. Int J Pharm 2001, 213:25-29.
17. Napoli K.L., Wang M.-E., Stepkowski S.M., Kahan B.D. Distribution of sirolimus in rat tissue. Clin Biochem 1997, 30:135-142.
18. Chen M.-C., Tsai H.-W., Liu C.-T., Peng S.-F., Lai W.-Y., Chen S.-J., et al. A nanoscale drug-entrapment strategy for hydrogel-based systems for the delivery of poorly soluble drugs. Biomaterials 2009, 30:2102-2111.
19. Yuan X.-B., Yuan Y.-B., Jiang W., Liu J., Tian E.-J., Shun H.-M., et al. Preparation of rapamycin-loaded chitosan/PLA nanoparticles for immunosuppression in corneal transplantation. Int J Pharm 2008, 349:241-248.
20. Forrest M.L., Won C.-Y., Malick A.W., Kwon G.S. In vitro release of the mTOR inhibitor rapamycin from poly(ethylene glycol)-b-poly([epsilon]-caprolactone) micelles. J Control Release 2006, 110:370-377.
21. Lu W., Li F., Mahato R.I. Poly(ethylene glycol)-block-poly(2-methyl-2-benzoxycarbonyl-propylene carbonate) micelles for rapamycin delivery: in vitro characterization and biodistribution. J Pharm Sci 2011, 100:2418-2429.
22. Bisht S., Feldmann G., Koorstra J.-B.M., Mullendore M., Alvarez H., Karikari C., et al. In vivo characterization of a polymeric nanoparticle platform with potential oral drug delivery capabilities. Mol Cancer Ther 2008, 7:3878-3888.
23. Parhi P., Mohanty C., Sahoo S.K. Enhanced cellular uptake and in vivo pharmacokinetics of rapamycin-loaded cubic phase nanoparticles for cancer therapy. Acta Biomater 2011, 7:3656-3669.
24. Maeda H. Tumor-selective delivery of macromolecular drugs via the EPR Effect: background and future prospects. Bioconjug Chem 2010, 21:797-802.
25. Stefanadis C., Chrysochoou C., Markou D., Petraki K., Panagiotakos D.B., Fasoulakis C., et al. Increased temperature of malignant urinary bladder tumors in vivo: the application of a new method based on a catheter technique. J Clin Oncol 2001, 19:676-681.
26. Lee E.S., Gao Z., Bae Y.H. Recent progress in tumor pH targeting nanotechnology. J Control Release 2008, 132:164-170.
27. Chen Y.-C., Liao L.-C., Lu P.-L., Lo C.-L., Tsai H.-C., Huang C.-Y., et al. The accumulation of dual pH and temperature responsive micelles in tumors. Biomaterials 2012, 33:4576-4588.
28. Nativo P., Prior I.A., Brust M. Uptake and intracellular fate of surface-modified gold nanoparticles. ACS Nano 2008, 2:1639-1644.
29. Pelkmans L., Bürli T., Zerial M., Helenius A. Caveolin-stabilized membrane domains as multifunctional transport and sorting devices in endocytic membrane traffic. Cell 2004, 118:767-780.
30. Venn A.A., Tambutté E., Lotto S., Zoccola D., Allemand D., Tambutté S. Imaging intracellular pH in a reef coral and symbiotic anemone. Proc Natl Acad Sci U S A 2009, 106:16574-16579.
31. Färber K., Schumann B., Miersch O., Roos W. Selective desensitization of jasmonate- and pH-dependent signaling in the induction of benzophenanthridine biosynthesis in cells of Eschscholzia californica. Phytochemistry 2003, 62:491-500.
32. Kim J.H., Johannes L., Goud B., Antony C., Lingwood C.A., Daneman R., et al. Noninvasive measurement of the pH of the endoplasmic reticulum at rest and during calcium release. Proc Natl Acad Sci U S A 1998, 95:2997-3002.
33. Kisiday J., Jin M., Kurz B., Hung H., Semino C., Zhang S., et al. Self-assembling peptide hydrogel fosters chondrocyte extracellular matrix production and cell division: implications for cartilage tissue repair. Proc Natl Acad Sci U S A 2002, 99:9996-10001.
34. Gref R., Domb A., Quellec P., Blunk T., Müller R.H., Verbavatz J.M., et al. The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres. Adv Drug Deliv Rev 1995, 16:215-233.
35. Pichon C., Gonçalves C., Midoux P. Histidine-rich peptides and polymers for nucleic acids delivery. Adv Drug Deliv Rev 2001, 53:75-94.
36. Soga O., van Nostrum C.F., Fens M., Rijcken C.J.F., Schiffelers R.M., Storm G., et al. Thermosensitive and biodegradable polymeric micelles for paclitaxel delivery. J Control Release 2005, 103:341-353.
37. Lo C.-L., Lin S.-J., Tsai H.-C., Chan W.-H., Tsai C.-H., Cheng C.-H.D., et al. Mixed micelle systems formed from critical micelle concentration and temperature-sensitive diblock copolymers for doxorubicin delivery. Biomaterials 2009, 30:3961-3970.
38. Park J., Kurosawa S., Watanabe J., Ishihara K. Evaluation of 2-Methacryloyloxyethyl phosphorylcholine polymeric nanoparticle for immunoassay of C-reactive protein detection. Anal Chem 2004, 76:2649-2655.
39. Hubbell J.A. Enhancing drug function. Science 2003, 300:595-596.
40. Tannock I.F., Rotin D. Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res 1989, 49:4373-4384.
41. Coffin M., McGinity J. Biodegradable pseudolatexes: the chemical stability of poly(d, l-lactide) and poly (ε-caprolactone) nanoparticles in aqueous media. Pharm Res 1992, 9:200-205.
42. Lo C.-L., Huang C.-K., Lin K.-M., Hsiue G.-H. Mixed micelles formed from graft and diblock copolymers for application in intracellular drug delivery. Biomaterials 2007, 28:1225-1235.
43. Tsai H.-C., Chang W.-H., Lo C.-L., Tsai C.-H., Chang C.-H., Ou T.-W., et al. Graft and diblock copolymer multifunctional micelles for cancer chemotherapy and imaging. Biomaterials 2010, 31:2293-2301.
44. Weiner I.D., Hamm L.L. Use of fluorescent dye BCECF to measure intracellular pH in cortical collecting tubule. Am J Physiol Renal Physiol 1989, 256:957-964.
45. Buckler K.J., Vaughan-Jones R.D. Application of a new pH-sensitive fluoroprobe (carboxy-SNARF-1) for intracellular pH measurement in small, isolated cells. Pflugers Arch 1990, 417:234-239.
46. Halamoda Kenzaoui B., Chapuis Bernasconi C., Guney-Ayra S., Juillerat-Jeanneret L. Induction of oxidative stress, lysosome activation and autophagy by nanoparticles in human brain-derived endothelial cells. Biochem J 2012, 441:813-821.
47. Yoo H.S., Park T.G. Biodegradable polymeric micelles composed of doxorubicin conjugated PLGA-PEG block copolymer. J Control Release 2001, 70:63-70.
48. Zhang Y., Kohler N., Zhang M. Surface modification of superparamagnetic magnetite nanoparticles and their intracellular uptake. Biomaterials 2002, 23:1553-1561.
49. Di L., Kerns E.H., Carter G.T. Drug-like property concepts in pharmaceutical design. Curr Pharm Des 2009, 15:2184-2194.
50. O'Donnell K.P., Williams R.O. Optimizing the formulation of poorly water-soluble drugs formulating poorly water soluble drugs 2012, 27-93. Springer, New York. R.O.O. Williams Iii, A.B.B. Watts, D.A.A. Miller (Eds.).
51. Witschi C., Doelker E. Residual solvents in pharmaceutical products: acceptable limits, influences on physicochemical properties, analytical methods and documented values. Eur J Pharm Biopharm 1997, 43:215-242.
52. Shepherd G. Hypersensitivity reactions to chemotherapeutic drugs. Clin Rev Allergy Immunol 2003, 24:253-262.
53. Hennenfent K.L., Govindan R. Novel formulations of taxanes: a review. Old wine in a new bottle?. Ann Oncol 2006, 17:735-749.
54. Kenerson H.L., Aicher L.D., True L.D., Yeung R.S. Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors. Cancer Res 2002, 62:5645-5650.
55. Vignot S., Faivre S., Aguirre D., Raymond E. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 2005, 16:525-537.
56. González-Polo R.-A., Boya P., Pauleau A.-L., Jalil A., Larochette N., Souquère S., et al. The apoptosis/autophagy paradox: autophagic vacuolization before apoptotic death. J Cell Sci 2005, 118:3091-3102.